Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 35 min ago
Peer-reviewedCC BY 4.0Frontiers in Cardiovascular Medicine

New onset atrial fibrillation after transcatheter aortic valve implantation in Southwestern Colombia between 2009 and 2023

7 affiliations
  1. 1Universidad Santiago de Cali
  2. 2Clinica de Occidente
  3. 3University of Caldas
  4. 4Ministerio de Salud Publica de Ecuador
  5. 5EpiHealth Research Center for Epidemiology and Public Health
  6. 6Vicerrectorado de Investigación, Universidad Señor de Sipán
  7. 7Oficina de Inteligencia Sanitaria, Red Prestacional Lambayeque

Abstract

Background: New-onset atrial fibrillation (NOAF) is an important complication after transcatheter aortic valve implantation (TAVI).

Methods: This retrospective cohort included 218 patients without documented pre-existing atrial fibrillation who underwent TAVI in Cali, Colombia, between 2009 and 2023. NOAF required an electrocardiographically documented episode lasting at least 30 s within 30 days. Clinical surveillance included inpatient telemetry and ECGs, scheduled follow-up and institutional readmissions; individual follow-up completeness was not quantified. We compared categorical characteristics and performed a sensitivity analysis restricted to recorded severe or critical aortic stenosis.

Results: NOAF was documented in 44/218 patients (20.2%; 95% CI, 15.4–26.0%). In the restricted subset, 35/164 had documented NOAF (21.3%; 95% CI, 15.8–28.2%). Chronic obstructive pulmonary disease was more frequent among patients with NOAF (61.4% versus 31.0%; unadjusted OR, 3.53; 95% CI, 1.78–7.01). Pacemaker implantation and low-molecular-weight heparin use were also more frequent in that group, describing perioperative co-occurrence.

Conclusion: Approximately one-fifth of patients had NOAF documented in the available records. Restriction to recorded severe or critical stenosis produced a similar frequency. The estimate describes clinical documentation within a 30-day window and requires interpretation in light of incomplete ascertainment and indication verification.

Related

  1. Incidence and timing of new-onset atrial fibrillation after transcatheter aortic valve implantation: 14-day electrocardiographic monitoring
    Arianna Sofia Bettelini, Céline Moser, Fabian Jordan +7
    Heart rhythm O2Peer-reviewedCC BYFull textCardiovascular medicineEurope PMC
  2. Leadless Pacemaker Implantation in Fabry Disease With Permanent Atrial Fibrillation and Bradycardia: Diagnostic and Implantation Guidance by Preprocedural Cardiac Magnetic Resonance Imaging.
    Hiroki Saito, Yuya Suzuki, Shinichiro Yamada +5
    Clinical case reportsPeer-reviewedCC BYFull textCardiovascular medicineEurope PMCPMC
  3. High Rates of Atrial Fibrillation among Inpatients with Heart Failure or Ischemic Stroke in Southwestern Uganda
    Peter K. Olds, Precious Twesigye, Lydia Nakawesa +3
    Annals of global healthPeer-reviewedCC BYFull textCardiovascular medicineEurope PMCPMC
  4. Prognostic Implications of Clinically Attributed Left Atrial Enlargement Subtypes in Patients Undergoing Transcatheter Aortic Valve Implantation.
    Tatsuya Sato, Asahiro Ito, Yuki Kitagawa +13
    Circulation reportsPeer-reviewedCC BY-NC-NDFull textCardiovascular medicineEurope PMCPMC
  5. Device-detected new-onset atrial fibrillation after dual-chamber pacemaker implantation in patients with sick sinus syndrome under managed ventricular pacing: a risk nomogram from the 3-month landmark
    Jin-Mei Xie, Cheng-Hua Shan, Ying-Jun Xiao +3
    Frontiers in Cardiovascular MedicinePeer-reviewedCC BY 4.0Cardiovascular medicineCrossref
BibTeX
@article{montenegropalacios2026onset,
  title = {{New onset atrial fibrillation after transcatheter aortic valve implantation in Southwestern Colombia between 2009 and 2023}},
  author = {John Fernando Montenegro-Palacios and Diana Marcela Bonilla and Antonio Enrique Dager and Jhon Quintana and Carlos Andrés Cardona and Nelson Murillo and Yamil Liscano and Jhony Alejandro Díaz Vallejo and Jamil Cedillo-Balcázar and Mario Valladares Garrido},
  journal = {Frontiers in Cardiovascular Medicine},
  year = {2026},
  month = nov,
  doi = {10.3389/fcvm.2026.1947079},
  url = {https://www.frontiersin.org/articles/10.3389/fcvm.2026.1947079/full},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - New onset atrial fibrillation after transcatheter aortic valve implantation in Southwestern Colombia between 2009 and 2023
AU  - John Fernando Montenegro-Palacios
AU  - Diana Marcela Bonilla
AU  - Antonio Enrique Dager
AU  - Jhon Quintana
AU  - Carlos Andrés Cardona
AU  - Nelson Murillo
AU  - Yamil Liscano
AU  - Jhony Alejandro Díaz Vallejo
AU  - Jamil Cedillo-Balcázar
AU  - Mario Valladares Garrido
PY  - 2026
DA  - 2026/11/16
JO  - Frontiers in Cardiovascular Medicine
DO  - 10.3389/fcvm.2026.1947079
UR  - https://www.frontiersin.org/articles/10.3389/fcvm.2026.1947079/full
AB  - Background: New-onset atrial fibrillation (NOAF) is an important complication after transcatheter aortic valve implantation (TAVI).  Methods: This retrospective cohort included 218 patients without documented pre-existing atrial fibrillation who underwent TAVI in Cali, Colombia, between 2009 and 2023. NOAF required an electrocardiographically documented episode lasting at least 30 s within 30 days. Clinical surveillance included inpatient telemetry and ECGs, scheduled follow-up and institutional readmissions; individual follow-up completeness was not quantified. We compared categorical characteristics and performed a sensitivity analysis restricted to recorded severe or critical aortic stenosis.  Results: NOAF was documented in 44/218 patients (20.2%; 95% CI, 15.4–26.0%). In the restricted subset, 35/164 had documented NOAF (21.3%; 95% CI, 15.8–28.2%). Chronic obstructive pulmonary disease was more frequent among patients with NOAF (61.4% versus 31.0%; unadjusted OR, 3.53; 95% CI, 1.78–7.01). Pacemaker implantation and low-molecular-weight heparin use were also more frequent in that group, describing perioperative co-occurrence.  Conclusion: Approximately one-fifth of patients had NOAF documented in the available records. Restriction to recorded severe or critical stenosis produced a similar frequency. The estimate describes clinical documentation within a 30-day window and requires interpretation in light of incomplete ascertainment and indication verification.
SN  - 2297-055X
ER  -